MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)-- Regulatory News:

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, announced today the receipt of the Frost & Sullivan 2011 European Molecular Diagnostics for Oncology Technology Leadership award. In giving the awards, Frost & Sullivan recognizes the strength and broad applicability of MDxHealth’s epigenetic technology platform in generating advanced tests for cancer assessment and the personalized treatment of patients.

“It is a great honor to receive this award from Frost & Sullivan,” noted Dr. Jan Groen, CEO of MDxHealth. “Our proprietary epigenetic technology, for which we are being recognized, forms the basis of all of our innovative cancer tests. It is good to see the hard work and dedication of all our employees being acknowledged independently.”

In bestowing the award, Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe said: “MDxHealth’s tests help distinguish between different levels of drug responders, while helping to accelerate the pharmaceutical development of a variety of drug therapies and demonstrating higher drug efficacy rates. Such new dynamic work styles enable the companies to overcome regulatory issues expediently, while simultaneously diminishing drug discovery and development costs.”

More information on the Award can be found on the Frost & Sullivan website: http://www.frost.com/prod/servlet/press-release.pag?docid=250886934

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company’s tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit the MDxHealth website at www.mdxhealth.com.

MDxHealth was recently profiled in the recent PWC Diagnostics 2011 report. The profile highlights the company’s change in strategy towards being a product based company that was implemented during 2011. Details of the report can be found on the PWC website (http://www.pwc.com/diagnostics2011).

Biotech Showcase 2012, January 9-11, San Francisco – Dr. Jan Groen will be presenting at the Biotech Showcase conference. Parties interested in meeting can contact Dr. Groen at the following : [email protected].

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation



CONTACT:

MDxHealth
Dr. Jan Groen, CEO
+32 4 364 20 70
[email protected]
or
Halsin Partners
Mike Sinclair
+44 20 7318 2955
[email protected]

KEYWORDS:   United States  Belgium  Europe  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Medical Devices  Oncology  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.